½ÃÀ庸°í¼­
»óǰÄÚµå
1798386

¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå - Áö¿ªº° ºÐ¼® : ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®°ú ¿¹Ãø(2025-2035³â)

Interventional Ultrasound Market - A Global and Regional Analysis: Focus on Application, End User, and Region - Analysis and Forecast, 2025-2035

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå ±Ô¸ð´Â 2024³â 22¾ï 3,870¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù.

ÀÌ ½ÃÀåÀº 2035³â¿¡´Â 42¾ï 2,370¸¸ ´Þ·¯·Î ±Þ¼ºÀåÇØ, 2025³âºÎÅÍ 2035³â±îÁö CAGR 6.05%·Î ÇöÀúÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2025-2035³â
2025³â Æò°¡ 23¾ï 4,800¸¸ ´Þ·¯
2035³â ¿¹Ãø 42¾ï 2,370¸¸ ´Þ·¯
CAGR 6.05%

ÀÌ ²ÙÁØÇÑ ¼ºÀåÀÇ ¹è°æÀº Àúħ½À Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ¸¸¼º ÁúȯÀÇ ¼¼°è ºÎ´ã Áõ°¡, ½ÉÀå º´ÇÐ ¹× Á¾¾çÇаú °°Àº ÀÓ»ó Àü¹® ºÐ¾ß Àüü¿¡¼­ À̹ÌÁö À¯µµ ÁßÀçÀÇ »ç¿ë È®´ë°¡ ÀÖ½À´Ï´Ù. ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ´Â ½Ç½Ã°£ Áöħ, ¹æ»ç¼± ³ëÃâ °¨¼Ò, ºñ¿ë È¿°ú µî ÀüÅëÀûÀÎ ¾ç½Ä¿¡ ºñÇØ ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖÀ¸¸ç, º´¿ø°ú ¿Ü·¡ ¸ðµÎ¿¡¼­ Á¡Á¡ ¸Å·ÂÀûÀÔ´Ï´Ù.

Á¶¿µ ÃÊÀ½ÆÄ, ¿¤¶ó½ºÅä±×·¡ÇÇ, ÀΰøÁö´É ±â¹Ý ÀÚµ¿È­¿Í °°Àº ±â¼ú Çõ½ÅÀ¸·Î ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛÀÇ Á¤È®¼º, »ç¿ë ÆíÀǼº ¹× Áø´Ü °¡Ä¡°¡ ´õ¿í Çâ»óµÇ¾ú½À´Ï´Ù. ±×·¯³ª ¿î¿µÀÚ¿¡ ´ëÇÑ ÀÇÁ¸¼º, È­ÁúÀÇ º¯µ¿, ƯÁ¤ Áö¿ªÀÇ »óȯ °úÁ¦ µîÀÇ Á¦¾àÀº ½ÃÀå ħÅõ¸¦ ¸·À» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À庮ÀÌ ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ¿¬±¸°³¹ßÀÇ Áö¼ÓÀûÀÎ ³ë·Â, ÀÓ»óÀû ¿ëµµ Áõ°¡, ½Ç½Ã°£ ºñ¹æ»ç À̹Ì¡¿¡ ´ëÇѼö¿ä Áõ°¡°¡ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ È®´ë¸¦ Áö¿øÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå µµÀÔ

ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀº Áö¼ÓÀûÀÎ ±â¼ú Áøº¸, Àü·«Àû Á¦ÈÞ, Àúħ½ÀÀ¸·Î ½Ç½Ã°£ ¿µ»ó À¯µµ¿¡ ÀÇÇÑ °³ÀÔÀ» Áß½ÃÇÏ´Â ÀÓ»ó ÀÀ¿ëÀÇ È®´ë¿¡ °ßÀεǾî Å« º¯Çõ±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ÀΰøÁö´É, 3D À̹ÌÁö, ¿¤¶ó½ºÅä±×·¡ÇÇ ¹× Á¶¿µ ÃÊÀ½ÆÄ¸¦ ÀÚü Ç÷§Æû¿¡ ÅëÇÕÇÏ¿© ±â¼úÀÇ Á¤È®¼º°ú ¿öÅ©Ç÷οì È¿À²À» ³ôÀÌ·Á°í ÇÕ´Ï´Ù. GE HealthCareÀÇ Versana Premier, Canon Inc.ÀÇ Aplio i ½Ã¸®Áî, Siemens Healthineers AGÀÇ AI ´ëÀÀ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛ µîÀÇ Çõ½ÅÀº ÀÌ·¯ÇÑ Ãß¼¼¸¦ ¹Ý¿µÇÕ´Ï´Ù. Àü·«Àû Àμö¿Í R&D ÅõÀÚ´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ ´õ¿í È®´ëÇÏ°í ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» °­È­Çϰí ÀÖ½À´Ï´Ù. ÃÊÀ½ÆÄ °¡À̵åÇÏ »ý°Ë, Á¾¾ç ¼ÒÀÛ¼ú, ¹ö½ºÅ§·¯ Á¢±Ù ÀýÂ÷°¡ ³Î¸® äÅõʿ¡ µû¶ó, ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ´Â ´Ù¾çÇÑ ÀÓ»ó ÇöÀå¿¡¼­ Á¤È®¼º, ¾ÈÀü¼º, ¹æ»ç¼±À» »ç¿ëÇÏÁö ¾Ê´Â ¿É¼ÇÀ» Á¦°øÇÏ´Â ÃֽŠÀ̹ÌÁö °¡À̵å ÇÏ Ä¡·á¹ýÀÇ ¿äÁ¡À¸·Î ÀÚ¸®¸Å±èÀÌ Á¡Á¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

»ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâ

¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀº ±¤¹üÀ§ÇÑ Ä¡·á ÀýÂ÷¿¡¼­ ½Ç½Ã°£À¸·Î ¹æ»ç¼±À» »ç¿ëÇÏÁö ¾Ê´Â À̹ÌÁö ¼Ö·ç¼Ç¿¡ ´ëÇѼö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÓ»ó ÇöÀå¿¡¼­ ÇöÀúÇÑ º¯È­¸¦ °æÇèÇϰí ÀÖ½À´Ï´Ù. Canon, Esaote SPA, GE HealthCare, Koninklijke Philips NV, Siemens Healthineers AG µîÀÇ ¾÷°è ¼±µÎÁÖÀÚ´Â ±âÁ¸ÀÇ Áø´Ü ¿ëµµ¿¡ ±×Ä¡Áö ¾Ê°í Á¤¹Ð À¯µµ °³ÀÔÀ» Áö¿øÇÏ´Â ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ±â¼úÀÇ Áøº¸¿¡ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Á¾¾çÇÐ, ½ÉÀ庴ÇÐ, ÀÀ±Þ ÀÇ·á¿¡ Áß¿äÇÑ µµ±¸·Î, ȯÀÚÀÇ ¿Ü»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ç¥ÀûÈ­µÈ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. º¹ÀâÇÑ ÀýÂ÷¸¦ °£¼ÒÈ­Çϰí Åõ½Ã ¹× CT ÀÇÁ¸µµ¸¦ ÁÙÀÌ°í ¿Ü·¡ ȯÀÚ¿Í ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ÀÇ Á¢±Ù¼ºÀ» °­È­ÇÔÀ¸·Î½á ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ´Â º¸´Ù È¿À²ÀûÀÎ ÀÇ·á Á¦°ø°ú ÀýÂ÷ °á°ú °³¼±¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó ´É·ÂÀ» È®´ëÇϰí Àúħ½ÀÀ¸·Î °¡Ä¡ ±â¹Ý °Ç°­ °ü¸®¸¦ ÇâÇÑ ¼¼°è µ¿ÇâÀ» Áö¿øÇÏ´Â ¿ªÇÒÀ» ÇÔÀ¸·Î½á ÀÌ ½ÃÀåÀÇ »ê¾÷¿¡ ´ëÇÑ ¿µÇâÀº ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼ºÐÈ­ 1: ¿ëµµº°

  • ÀÏ¹Ý ¿Ü°ú
  • ¾Ï
  • ½ÉÀå ¹× Ç÷°ü³»
  • ±âŸ

ÀÏ¹Ý ¼ö¼ú ºÎ¹®ÀÌ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀ» µ¶Á¡(¿ëµµº°)

¿ëµµº°·Î ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀº ÀÏ¹Ý ¼ö¼úÀÌ °ßÀÎÇÏ¿© 2024³â¿¡´Â 39.8%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡ÇÏ´Â ÁÖµÈ ÀÌÀ¯´Â ±¤¹üÀ§ÇÑ ÀÓ»ó Àû À¯¿ë¼º°ú Àúħ½À ¼ö¼ú ½Ã½ºÅÛÀÇ Ã¤¿ë Áõ°¡ ¶§¹®ÀÔ´Ï´Ù. ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ´Â »ý°Ë, ü¾× ¹è¼ö, Á¾¾ç ÀýÁ¦, Ç÷°ü Á¢±Ù°ú °°Àº ½Ç½Ã°£ ÁöħÀ» À§ÇØ ÀÏ¹Ý ¼ö¼ú¿¡¼­ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹æ»ç¼±À» Á¶»çÇÏÁö ¾Ê°í µ¿Àû ½Ç½Ã°£ À̹ÌÁö¸¦ Á¦°øÇÒ ¼ö Àֱ⠶§¹®¿¡ ¼ö¼ú Áß ÀÇ»ç °áÁ¤°ú Á¤¹ÐÇÑ Å¸°ÙÆÃ¿¡ ÀÌ»óÀûÀÎ ¾ç½ÄÀÔ´Ï´Ù.

¼¼ºÐÈ­ 2: ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ(¿¬±¸¿ë)

ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀ» µ¶Á¡ÇÏ´Â °ÍÀº º´¿ø ¹× Áø·á¼Ò ºÎ¹®(ÃÖÁ¾ »ç¿ëÀÚº°)

ÃÖÁ¾ »ç¿ëÀÚº°·Î ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀº º´¿ø ¹× Áø·á¼Ò ºÎ¹®ÀÌ °ßÀÎÇßÀ¸¸ç 2024³â Á¡À¯À²Àº 79.1%¿´½À´Ï´Ù. º´¿ø ¹× Ŭ¸®´ÐÀº °íµµ·Î ´ë·®ÀÇ ÁýÁßÀûÀÎ ÀÎÅͺ¥¼Ç Ä¡·á¸¦ Á¦°øÇϴµ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ÃÖÁ¾ »ç¿ëÀÚº°·Î ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ÷´Ü ÀÎÇÁ¶ó, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡, ÀÏ¹Ý ¿Ü°ú, Á¾¾ç°ú, ¼øÈ¯±â°ú, ÀÀ±Þ°ú °°Àº Àü¹® ºÎ¹®À» °®Ãá º´¿øÀº ±¤¹üÀ§ÇÑ Ä¡·á¿¡ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛÀ» µµÀÔÇϰí Ȱ¿ëÇϱ⿡ ÀÌ»óÀûÀÎ ÀÔÀå¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Àúħ½À ÀÎÅͺ¥¼Ç¿¡¼­ Á¤È®ÇÏ°í ½Ç½Ã°£ ÁöħÀ» °¡´ÉÇÏ°Ô ÇÏ°í °á±¹ Ä¡·á °á°ú¸¦ °³¼±Çϰí ȯÀÚÀÇ È¸º¹ ½Ã°£À» ´ÜÃàÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. º´¿ø ¹× Áø·á¼Ò°¡ AI ÅëÇÕÇü ¹× ÈÞ´ë¿ë ÃÊÀ½ÆÄ Ç÷§Æû°ú °°Àº Â÷¼¼´ë ±â¼ú¿¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» °®Ãß°í ÀÖ´Ù´Â °ÍÀº ÀÌ ºÐ¾ßÀÇ ÁÖµµ±ÇÀ» ´õ¿í Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÓ»ó ÇöÀå¿¡¼­ ¿Ü·¡ ȯÀÚ¿Í µ¥ÀÌÄɾî·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ º´¿ø ¹× Ŭ¸®´ÐÀ» ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ µµÀÔÀÇ ¿äÁ¡À¸·Î ½ÃÀå Á¡À¯À²À» °­È­Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹® 3: Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È 7.06%¶ó´Â ´ëÆøÀûÀÎ ¼ºÀå·üÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ °­·ÂÇÑ ¼ºÀå ±Ëµµ´Â °Ç°­ °ü¸® ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ Áøº¸, Àúħ½À óġ¿¡ ´ëÇѼö¿ä Áõ°¡, ¼ö¼ú ¹× Áø´Ü ÇöÀå¿¡¼­ ½Ç½Ã°£ À̹Ì¡ ±â¼ú äÅà Áõ°¡¿Í °°Àº º¹ÇÕ ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ƯÈ÷ Áß±¹, ÀϺ», Çѱ¹, Àεµ µî ±¹°¡¿¡¼­ °¡Àå ±â¼úÀûÀ¸·Î ÁøÇàµÈ º´¿ø°ú Çмú±â°üÀÇ º»°ÅÁö·Î Á¤¹ÐÀÇ·á ¹× È­»óÀ¯µµÄ¡·á¿¡ ´ëÇÑ ÅõÀÚ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÌ Áö¿ªÀº ȯÀÚ¼ö°¡ ¸¹¾Æ ¾Ï, ½ÉÇ÷°üÁúȯ, °£Áúȯ µî ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ´Ù¾çÇÑ Àü¹® ºÐ¾ß¿¡¼­ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

  • 2024³â 2¿ù, Canon Inc.´Â ÀÓ»ó ¿öÅ©Ç÷οì¿Í ȯÀÚ °ü¸®¸¦ °³¼±Çϱâ À§ÇØ Ã·´Ü À̹Ì¡ ±â´É°ú ÀÎü°øÇÐÀû ¼³°è¸¦ ÅëÇÕÇÑ ÄÄÆÑÆ®Çϰí ģȯ°æÀûÀÎ ÃÊÀ½ÆÄ Áø´Ü ½Ã½ºÅÛÀÎ Aplio beyond¸¦ ¹ßÇ¥Çß½À´Ï´Ù.
  • 2025³â 1¿ù, GE HealthCare´Â Voluson Expert 22, 20, 18À» Æ÷ÇÔÇÑ Voluson Expert ½Ã¸®Áî ÃÊÀ½ÆÄ Áø´Ü ÀåÄ¡ÀÇ FDA 510(k) Àΰ¡¸¦ ¹Þ¾Ò½À´Ï´Ù. Voluson Expert 22, 20, 18Àº °í±Þ ÀΰøÁö´É ±â´É, Çâ»óµÈ À̹ÌÁö ó¸® µµ±¸ ¹× ÀÎü °øÇÐÀû µðÀÚÀÎÀ» ÅëÇÕÇÏ¿© ¿©¼º ÀÇ·á, ƯÈ÷ °íÀ§Çè ÀÓ½ÅÀÇ ¿öÅ©Ç÷οì È¿À²¼º°ú Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ãŵ´Ï´Ù.
  • 2024³â 8¿ù, Koninklijke Philips NV´Â Carilion Clinic°ú Á¦ÈÞÇÏ¿© Crystal Spring Tower¿¡ ½Å¼³µÈ ½ÉÀåÇ÷°ü ¿¬±¸¼Ò¿¡ 11°³ÀÇ °í±Þ ÀÎÅͺ¥¼Å³Î ½ºÀ§Æ®¸¦ µµÀÔÇß½À´Ï´Ù.
  • 2024³â 4¿ù, Esaote GroupÀº ÀÚȸ»çÀÎ Esaote Asia-Pacific Diagnostic Private Limited¸¦ ÅëÇØ Àεµ ¿ìŸ¸£ ÇÁ¶óµ¥½Ã ÁÖ¿¡ »õ·Î¿î Á¦Á¶ ½Ã¼³À» ¼³¸³ÇÏ¿© ÇöÁö ½ÃÀåÀ» À§ÇÑ Ã·´Ü ÀεµÁ¦ ÃÊÀ½ÆÄ Áø´Ü ½Ã½ºÅÛÀ» Á¦Á¶ÇÕ´Ï´Ù. ÀÌ ½Ã¼³Àº AI¸¦ Ȱ¿ëÇÑ È®Àå ÅëÂû ±â¼ú°ú Çõ½ÅÀûÀÎ ÅÍÄ¡ ½ºÅ©¸° ÄÁÆ®·ÑÀ» Ư¡À¸·Î ÇÏ´Â MyLab A, MyLab E ½Ã¸®Áî, ÄÄÆÑÆ®ÇÑ ÈÞ´ë¿ë ¸ðµ¨À» Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù.

¼ö¿ä - ÃËÁø¿äÀÎ, µµÀü, ±âȸ

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

Àúħ½À ¼ö¼ú¿¡ ´ëÇѼö¿ä Áõ°¡ : Àúħ½À ¼ö¼ú¿¡ ´ëÇѼö¿ä Áõ°¡´Â ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Àúħ½À ÀýÂ÷´Â °¨¿° À§ÇèÀÇ °¨¼Ò¿Í ȸº¹ ½Ã°£ÀÇ »ó´çÇÑ ´ÜÃà°ú °°Àº ÀüÅëÀûÀÎ °³º¹ ¼ö¼ú¿¡ ´ëÇÑ ¸íÈ®ÇÑ ÀÌÁ¡À» Á¦°øÇÔÀ¸·Î½á °Ç°­ °ü¸®ÀÇ »óȲÀ» º¯È­½Ãŵ´Ï´Ù. Paragon Surgical Center¿¡ µû¸£¸é, Àúħ½À Ä¡·á¸¦ ¹ÞÀº ȯÀÚ´Â ÀϹÝÀûÀ¸·Î °³º¹ ¼ö¼ú°ú °ü·ÃµÈ ȸº¹ ±â°£ÀÇ Àå±âÈ­¿Í ºñ±³ÇÏ¿© ¸çÄ¥¿¡¼­ ¼öÁÖ µ¿¾È Á¤»óÀûÀΠȰµ¿À» Àç°³ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ´Â »ý°Ë, Á¾¾ç ÀýÁ¦, Ç÷°ü Á¢±Ù µîÀÇ Ä¡·á ½Ã Á¤È®ÇÑ Å¸°ÙÆÃÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ½Ç½Ã°£ ¹«¹æ»ç¼± À̹Ì¡À» Á¦°øÇÔÀ¸·Î½á ÀÌ º¯È­¿¡ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â º¸Á¶ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀýÂ÷ÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ ¸¸¼ºÁúȯÀÇ ¼¼°è ºÎ´ãÀÌ Áõ°¡Çϰí ȯÀÚÀÇ ¼±È£µµ°¡ º¸´Ù ½Å¼ÓÇϰí ħ½ÀÀÌ ÀûÀº Ä¡·á·Î À̵¿ÇÔ¿¡ µû¶ó ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛÀÇ Ã¤¿ëÀÌ ´Ù¾çÇÑ ÀÓ»ó ÇöÀå¿¡¼­ °¡¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀåÀÇ °úÁ¦

Àåºñ ¹× Ä¡·á ºñ¿ë : °í±Þ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛÀº ÀÓ»óÀû ÀÌÁ¡¿¡µµ ºÒ±¸ÇÏ°í ºñ¿ëÀÌ ³ô±â ¶§¹®¿¡ ƯÈ÷ ºñ¿ë¿¡ ¹Î°¨Çϰí ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­´Â º¸´Ù ±¤¹üÀ§ÇÑ º¸±ÞÀ» ¸·´Â Å« À庮ÀÌ µÇ¾ú½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¼ÒÇÁÆ®¿þ¾î¿Í Á¶¿µ ±â´ÉÀ» °®Ãá ÇÏÀÌ¿£µå ÃÊÀ½ÆÄ Ç÷§ÆûÀº ´ë±Ô¸ð ¼³ºñ ÅõÀÚ¸¦ ÇÊ¿ä·Î Çϱ⠶§¹®¿¡ ¼Ò±Ô¸ð Ŭ¸®´ÐÀ̳ª °ø°ø ÀÇ·á±â°ü¿¡¼­´Â ÀÌ¿ëÇÏ±â ¾î·Æ½À´Ï´Ù. ¶ÇÇÑ ÀÏȸ¿ë ±â±¸ ¹× Áö¼ÓÀûÀÎ À¯Áöº¸¼ö¿Í °°Àº Ä¡·á¿Í °ü·ÃµÈ ºñ¿ëÀº ÀÇ·á ¿¹»êÀ» ´õ¿í ¾Ð¹ÚÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºñ¿ë Á¦¾àÀ¸·Î ÀÎÇØ °í±Þ ¿µ»ó Áø´Ü¿¡ ´ëÇÑ ¾×¼¼½º°¡ ÀÌ¹Ì Á¦ÇÑµÈ Áö¿ªÀ̳ª ¼­ºñ½º°¡ ÃæºÐÇÏÁö ¾ÊÀº Áö¿ª¿¡¼­ÀÇ ¹èÆ÷°¡ Á¦Çѵ˴ϴÙ. ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ±â¼úÀ» ¼¼°èÀûÀ¸·Î º¸´Ù °øÁ¤ÇÏ°Ô º¸±ÞÇϱâ À§Çؼ­´Â ÀÌ·¯ÇÑ °¡°Ý ¸é¿¡¼­ÀÇ °úÁ¦¿¡ ´ëóÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ±âȸ

½ÅÈï ½ÃÀå È®´ë : ½ÅÈï ½ÃÀåÀº ÇコÄɾî ÅõÀÚ Áõ°¡, ÀÎÇÁ¶ó °³¼±, ħ½À±â¼ú¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå¿¡ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ±¹°¡¿¡¼­´Â ÀÇ·áºñÀÇ ±Þ°ÝÇÑ ¼ºÀå°ú ¸¸¼º ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ¿© È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿°úÀûÀÎ À̹ÌÁö ¼Ö·ç¼Ç¿¡ ´ëÇѼö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü ¹× Ä¡·á µµ±¸¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ Á¤ºÎ ¹× ¼¼°è ÀÇ·á±â°üÀÇ ³ë·ÂÀÌ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÇöÁö ÆÄÆ®³Ê½Ê, ±³À° ÇÁ·Î±×·¥ ¹× Áö¿ªº° Á¦Ç° ¶óÀÎÀ» ÅëÇØ ÇöÀç »óŸ¦ È®´ëÇÏ´Â ½ÃÀå ÁøÃâ ±â¾÷Àº ÀÌ·¯ÇÑ ±Þ¼ºÀå °æÁ¦±ÇÀÇ ¹Ì°³Ã´ °¡´É¼ºÀ¸·ÎºÎÅÍ Å« ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

Á¦Ç° ¹× À̳뺣ÀÌ¼Ç Àü·« : ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀº ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª µî ´Ù¾çÇÑ Ä«Å×°í¸®¸¦ ±â¹ÝÀ¸·Î ±¤¹üÀ§ÇÏ°Ô ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ µ¶ÀÚ´Â ¾î¶² ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´ÂÁö, ±×¸®°í ¾î¶² ºÎ¹®ÀÌ ÇâÈÄ ¸î ³â µ¿¾È ¼ºÀåÇÒ °ÍÀÎÁö¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼ºÀå ¹× ¸¶ÄÉÆÃ Àü·« : ÁÖ¿ä °³¹ßÀº ½Å±Ô °³¹ßÀÌ °¡Àå ¸¹À¸¸ç 2021³â 1¿ùºÎÅÍ 2025³â 5¿ù±îÁö ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ¼¼°è ½ÃÀåÀÇ °³¹ß ÀüüÀÇ ¾à 58.1%¸¦ Â÷ÁöÇß½À´Ï´Ù.

°æÀï Àü·« : ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå¿¡´Â Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °¡Áø ¸¹Àº ±âÁ¸ ±â¾÷ÀÌ ÀÖ½À´Ï´Ù. º» ¿¬±¸¿¡¼­ ºÐ¼® ¹× ÇÁ·ÎÆÄÀϸµÇÑ ¼¼°è ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ¿¡´Â ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½Ã½ºÅÛ Á¦Ç°À» Á¦°øÇÏ´Â ±âÁ¸ ±â¾÷ÀÌ Æ÷ÇԵ˴ϴÙ.

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå : ¾÷°è Àü¸Á

  • ÁÖ¿ä ½ÃÀå µ¿Çâ
    • ¿µÇ⠺м®
    • ÃÊÀ½ÆÄ ½Ã½ºÅÛ¿¡ ÀΰøÁö´É ÅëÇÕ
    • ÃÊÀ½ÆÄ ½Ã½ºÅÛ Á¦Ç° Ãâ½Ã Áõ°¡
  • ƯÇ㠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • °¡°Ý ºÐ¼®
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀåÀÇ °úÁ¦
    • ½ÃÀå ±âȸ

Á¦2Àå ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå(¿ëµµº°), 2023-2035³â

  • ÀÏ¹Ý ¿Ü°ú
  • ¾Ï
  • ½ÉÀåÇ÷°ü ³»°ú
  • ±âŸ

Á¦3Àå ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå(ÃÖÁ¾ »ç¿ëÀÚº°), 2023-2035³â

  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦4Àå ¼¼°èÀÇ ÀÎÅͺ¥¼Å³Î ÃÊÀ½ÆÄ ½ÃÀå(Áö¿ªº°), 2023-2035³â

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦5Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • °æÀï ±¸µµ
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Canon Inc.
    • DeepSight Technology, Inc.
    • Edan Instruments
    • Esaote SPA
    • FUJIFILM Holdings Corporation
    • GE HealthCare
    • Konica Minolta, Inc.
    • Koninklijke Philips NV
    • Samsung Healthcare
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Siemens Healthineers AG
    • SonoScape Medical Corp.

Á¦6Àå Á¶»ç ¹æ¹ý

JHS 25.09.03

This report can be delivered within 1 working day.

Introduction of Interventional Ultrasound Market

The global interventional ultrasound market, initially valued at $2,238.7 million in 2024, is projected to witness substantial growth, surging to $4,223.7 million by 2035, marking a remarkable compound annual growth rate (CAGR) of 6.05% over the period from 2025 to 2035.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$2,348.0 Million
2035 Forecast$4,223.7 Million
CAGR6.05%

This steady growth is being driven by the increasing preference for minimally invasive procedures, a rising global burden of chronic diseases, and the expanding use of image-guided interventions across clinical specialties such as cardiology and oncology. Interventional ultrasound offers several advantages over traditional modalities, including real-time guidance, reduced radiation exposure, and cost-effectiveness, making it increasingly attractive for both hospital and outpatient settings.

Technological innovations, such as the incorporation of contrast-enhanced ultrasound, elastography, and artificial intelligence-based automation, are further enhancing the precision, usability, and diagnostic value of interventional ultrasound systems. However, limitations such as operator dependency, variability in image quality, and reimbursement challenges in certain regions may constrain market penetration. Despite these barriers, ongoing R&D efforts, increasing clinical applications, and growing demand for real-time, non-radiative imaging are expected to support the sustained expansion of the interventional ultrasound market.

Market Introduction

The interventional ultrasound market has been undergoing significant transformation, driven by continuous technological advancements, strategic partnerships, and expanding clinical applications that emphasize minimally invasive, real-time image-guided interventions. Companies are increasingly integrating artificial intelligence, 3D imaging, elastography, and contrast-enhanced ultrasound into their platforms to enhance procedural accuracy and workflow efficiency. Innovations such as GE HealthCare's Versana Premier, Canon Inc.'s Aplio i-series, and Siemens Healthineers AG's AI-enabled interventional ultrasound systems reflect this trend. Strategic acquisitions and R&D investments are further broadening product portfolios and reinforcing market presence. As ultrasound-guided biopsies, tumor ablation, and vascular access procedures become more widely adopted, interventional ultrasound is increasingly positioned as a cornerstone of modern image-guided therapeutics, offering precision, safety, and radiation-free alternatives across diverse clinical settings.

Industrial Impact

The global interventional ultrasound market has been experiencing a notable shift in clinical practice, driven by growing demand for real-time, radiation-free imaging solutions across a wide range of therapeutic procedures. Industry leaders such as Canon Inc., Esaote SPA, GE HealthCare, Koninklijke Philips N.V., and Siemens Healthineers AG have been playing a central role in advancing interventional ultrasound technologies that support precision-guided interventions beyond traditional diagnostic applications. These systems are critical tools in oncology, cardiology, and emergency medicine, enabling targeted treatments with minimal patient trauma. By streamlining complex procedures, reducing reliance on fluoroscopy or CT, and enhancing access in outpatient and resource-limited settings, interventional ultrasound has been contributing to more efficient care delivery and improved procedural outcomes. The market's industrial impact is further amplified by its role in broadening clinical capabilities and supporting the global trend toward minimally invasive, value-based healthcare.

Market Segmentation:

Segmentation 1: by Application

  • General Surgery
  • Cancer
  • Cardiac and Endovascular
  • Others

General Surgery Segment to Dominate the Interventional Ultrasound Market (by Application)

Based on application, the global interventional ultrasound market was led by general surgery, which held a 39.8% share in 2024. The segment dominates the market primarily due to its broad clinical utility and increasing adoption of minimally invasive surgical systems. Interventional ultrasound is increasingly being used in general surgical procedures for real-time guidance in biopsies, fluid drainage, tumor ablation, and vascular access. Its ability to provide dynamic, real-time imaging without radiation exposure makes it an ideal modality for intraoperative decision-making and precision targeting.

Segmentation 2: by End User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others (Research Use)

Hospitals and Clinics Segment to Dominate the Interventional Ultrasound Market (by End User)

Based on end user, the global interventional ultrasound market was led by the hospitals and clinics segment, which held a 79.1% share in 2024. Hospitals and clinics dominate the interventional ultrasound market based on end-users due to the pivotal role hospitals and large clinical centers play in delivering advanced, high-volume, and multidisciplinary interventional care. Equipped with state-of-the-art infrastructure, skilled healthcare professionals, and dedicated departments such as general surgery, oncology, cardiology, and emergency medicine, hospitals are ideally positioned to adopt and utilize interventional ultrasound systems for a wide range of procedures. These systems are essential for enabling precise, real-time guidance during minimally invasive interventions, ultimately improving procedural outcomes and reducing patient recovery times. The capacity of hospitals and clinics to invest in next-generation technologies, including AI-integrated and portable ultrasound platforms, further supports their leadership in this segment. Moreover, the increasing shift toward outpatient and day-care procedures within clinical settings continues to reinforce their market share, making hospitals and clinics the cornerstone of interventional ultrasound adoption globally.

Segmentation 3: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa

The interventional ultrasound market in the Asia-Pacific region is expected to witness a significant growth rate of 7.06% during the forecast period. This strong growth trajectory is driven by a combination of factors, including rapid advancements in healthcare infrastructure, rising demand for minimally invasive procedures, and the increasing adoption of real-time imaging technologies across surgical and diagnostic settings. Asia-Pacific is home to some of the most technologically advanced hospitals and academic institutions, particularly in countries such as China, Japan, South Korea, and India, where there is growing investment in precision medicine and image-guided therapies. Additionally, the region's large patient population and increasing prevalence of chronic conditions such as cancer, cardiovascular disease, and liver disorders have been fueling the demand for interventional ultrasound across a variety of specialties.

Recent Developments in the Interventional Ultrasound Market

  • In February 2024, Canon Inc. introduced the Aplio beyond, a compact, eco-friendly ultrasound system that integrates advanced imaging capabilities with ergonomic design, aiming to enhance clinical workflows and patient care.
  • In January 2025, GE HealthCare has received FDA 510(k) clearance for its updated Voluson Expert Series ultrasound systems, including the Voluson Expert 22, 20, and 18, which integrate advanced artificial intelligence features, enhanced imaging tools, and ergonomic design to improve workflow efficiency and diagnostic accuracy in women's healthcare, particularly for high-risk pregnancies.
  • In August 2024, Koninklijke Philips N.V. partnered with Carilion Clinic to equip the new Cardiovascular Institute at Crystal Spring Tower with 11 advanced interventional suites, integrating cutting-edge imaging and ultrasound technologies to enhance cardiovascular care and optimize clinical performance for complex procedures.
  • In April 2024, Esaote Group established a new manufacturing facility in Uttar Pradesh, India, through its subsidiary Esaote Asia-Pacific Diagnostic Private Limited, to produce advanced Made in India ultrasound systems for the local market. The site is expected to deliver the MyLab A, MyLab E series, and compact portable models, all featuring AI-powered augmented insight technology and innovative touchscreen controls.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Rising Demand for Minimally Invasive Procedures: The increasing demand for minimally invasive procedures is a key driver of the interventional ultrasound market. Minimally invasive techniques have been transforming the healthcare landscape by offering clear advantages over traditional open surgeries, including a lower risk of infection and significantly faster recovery times. According to Paragon Surgical Center, patients undergoing minimally invasive treatments can typically resume normal activities within days or weeks, compared to the extended recovery periods associated with open surgeries. Interventional ultrasound plays a central role in this transformation by providing real-time, radiation-free imaging that allows for precise targeting during procedures such as biopsies, tumor ablations, and vascular access. This not only minimizes collateral tissue damage but also enhances procedural accuracy and safety. Further, as the global burden of chronic conditions rises and patient preferences shift toward quicker and less invasive treatments, the adoption of interventional ultrasound systems is expected to accelerate across diverse clinical settings.

Market Challenges

High Cost of Equipment and Procedures: Despite its clinical benefits, the high cost associated with advanced interventional ultrasound systems remains a significant barrier to broader adoption, particularly in cost-sensitive and resource-limited environments. High-end ultrasound platforms equipped with AI-driven software and contrast-enhanced imaging features demand substantial capital investment, making them less accessible to smaller clinics or public healthcare institutions. Moreover, procedure-related expenses, including disposable instruments and ongoing maintenance, can further strain healthcare budgets. These cost constraints limit deployment in rural and underserved regions, where access to advanced imaging is already restricted. Addressing these affordability challenges is expected to be crucial to achieving more equitable adoption of interventional ultrasound technology worldwide.

Market Opportunities

Expansion in Emerging Markets: Emerging markets present a substantial growth opportunity for the interventional ultrasound market, driven by rising healthcare investments, improving infrastructure, and increasing awareness of minimally invasive techniques. Countries in Asia-Pacific, Latin America, and the Middle East have been witnessing rapid growth in healthcare expenditure and a growing burden of chronic diseases, creating demand for scalable and cost-effective imaging solutions. Additionally, initiatives by governments and global health organizations to improve access to diagnostic and therapeutic tools are accelerating the adoption of interventional ultrasound systems. Market players expanding their presence through local partnerships, training programs, and region-specific product lines stand to benefit significantly from the untapped potential in these fast-growing economies.

How can this report add value to an organization?

Product/Innovation Strategy: The global interventional ultrasound market has been extensively segmented based on various categories, such as application, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: New offerings accounted for the maximum number of key developments, i.e., nearly 58.1% of the total developments in the global interventional ultrasound market were between January 2021 and May 2025.

Competitive Strategy: The global interventional ultrasound market has numerous established players with product portfolios. Key players in the global interventional ultrasound market analyzed and profiled in the study include established players offering products for interventional ultrasound systems.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2022-FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report presents a comprehensive market study of the upstream and downstream products in the interventional ultrasound market.
  • The market contribution of interventional ultrasound is anticipated to be launched in the future and has been calculated based on the historical analysis of the solutions.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available interventional ultrasound systems. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research

The primary sources involve industry experts in interventional ultrasound, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Canon Inc.
  • DeepSight Technology, Inc.
  • Edan Instruments
  • Esaote SPA
  • FUJIFILM Holdings Corporation
  • GE HealthCare
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • Samsung Healthcare
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthineers AG
  • SonoScape Medical Corp.

Table of Contents

Executive Summary

Scope and Definition

1 Global Interventional Ultrasound Market: Industry Outlook

  • 1.1 Key Market Trends
    • 1.1.1 Impact Analysis
    • 1.1.2 Integration of Artificial Intelligence in Ultrasound Systems
    • 1.1.3 Increase in Ultrasound System Product Launch
  • 1.2 Patent Analysis
    • 1.2.1 Patent Filing Trend (by Country)
    • 1.2.2 Patent Filing Trend (by Year)
  • 1.3 Regulatory Landscape
    • 1.3.1 U.S.
    • 1.3.2 Europe
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
      • 1.3.3.3 India
      • 1.3.3.4 Australia
  • 1.4 Pricing Analysis
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Rising Demand for Minimally Invasive Procedures
      • 1.5.1.2 Growing Prevalence of Chronic Diseases
      • 1.5.1.3 Technological Advancements
    • 1.5.2 Market Challenges
      • 1.5.2.1 High Cost of Equipment and Procedures
      • 1.5.2.2 Shortage of Skilled Professionals
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Expansion in Emerging Markets

2 Global Interventional Ultrasound Market (by Application), ($Million), 2023-2035

  • 2.1 General Surgery
  • 2.2 Cancer
    • 2.2.1 Lung Cancer
    • 2.2.2 Breast Cancer
    • 2.2.3 Liver Cancer
    • 2.2.4 Kidney Cancer
    • 2.2.5 Prostate Cancer
    • 2.2.6 Others
  • 2.3 Cardiac and Endovascular
  • 2.4 Others

3 Global Interventional Ultrasound Market (by End User), ($Million), 2023-2035

  • 3.1 Hospitals and Clinics
  • 3.2 Ambulatory Surgical Centers
  • 3.3 Others

4 Global Interventional Ultrasound Market (by Region), ($Million), 2023-2035

  • 4.1 North America
    • 4.1.1 Regional Overview
    • 4.1.2 Driving Factors for Market Growth
    • 4.1.3 Factors Challenging the Market
    • 4.1.4 Market Sizing and Forecast
      • 4.1.4.1 North America Interventional Ultrasound Market, by Application
      • 4.1.4.2 North America Interventional Ultrasound Market, by End User
      • 4.1.4.3 North America Interventional Ultrasound Market, by Country
        • 4.1.4.3.1 U.S.
          • 4.1.4.3.1.1 Country Overview
          • 4.1.4.3.1.2 Market Sizing and Forecast
          • 4.1.4.3.1.2.1 U.S. Interventional Ultrasound Market, by End User
        • 4.1.4.3.2 Canada
          • 4.1.4.3.2.1 Country Overview
          • 4.1.4.3.2.2 Market Sizing and Forecast
          • 4.1.4.3.2.2.1 Canada Interventional Ultrasound Market, by End User
  • 4.2 Europe
    • 4.2.1 Regional Overview
    • 4.2.2 Driving Factors for Market Growth
    • 4.2.3 Factors Challenging the Market
    • 4.2.4 Market Sizing and Forecast
      • 4.2.4.1 Europe Interventional Ultrasound Market, by Application
      • 4.2.4.2 Europe Interventional Ultrasound Market, by End User
      • 4.2.4.3 Europe Interventional Ultrasound Market, by Country
        • 4.2.4.3.1 U.K.
          • 4.2.4.3.1.1 Country Overview
          • 4.2.4.3.1.2 Market Sizing and Forecast
          • 4.2.4.3.1.2.1 U.K. Interventional Ultrasound Market, by End User
        • 4.2.4.3.2 France
          • 4.2.4.3.2.1 Country Overview
          • 4.2.4.3.2.2 Market Sizing and Forecast
          • 4.2.4.3.2.2.1 France Interventional Ultrasound Market, by End User
        • 4.2.4.3.3 Germany
          • 4.2.4.3.3.1 Country Overview
          • 4.2.4.3.3.2 Market Sizing and Forecast
          • 4.2.4.3.3.2.1 Germany Interventional Ultrasound Market, by End User
        • 4.2.4.3.4 Italy
          • 4.2.4.3.4.1 Country Overview
          • 4.2.4.3.4.2 Market Sizing and Forecast
          • 4.2.4.3.4.2.1 Italy Interventional Ultrasound Market, by End User
        • 4.2.4.3.5 Spain
          • 4.2.4.3.5.1 Country Overview
          • 4.2.4.3.5.2 Market Sizing and Forecast
          • 4.2.4.3.5.2.1 Spain Interventional Ultrasound Market, by End User
        • 4.2.4.3.6 Rest-of-Europe
          • 4.2.4.3.6.1 Country Overview
          • 4.2.4.3.6.2 Market Sizing and Forecast
          • 4.2.4.3.6.3 Rest-of-Europe Interventional Ultrasound Market, by End User
  • 4.3 Asia-Pacific
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
    • 4.3.4 Market Sizing and Forecast
      • 4.3.4.1 Asia-Pacific Interventional Ultrasound Market, by Application
      • 4.3.4.2 Asia-Pacific Interventional Ultrasound Market, by End User
      • 4.3.4.3 Asia-Pacific Interventional Ultrasound Market, by Country
        • 4.3.4.3.1 Japan
          • 4.3.4.3.1.1 Country Overview
          • 4.3.4.3.1.2 Market Sizing and Forecast
          • 4.3.4.3.1.2.1 Japan Interventional Ultrasound Market, by End User
        • 4.3.4.3.2 China
          • 4.3.4.3.2.1 Country Overview
          • 4.3.4.3.2.2 Market Sizing and Forecast
          • 4.3.4.3.2.3 China Interventional Ultrasound Market, by End User
        • 4.3.4.3.3 India
          • 4.3.4.3.3.1 Country Overview
          • 4.3.4.3.3.2 Market Sizing and Forecast
          • 4.3.4.3.3.2.1 India Interventional Ultrasound Market, by End User
        • 4.3.4.3.4 Australia
          • 4.3.4.3.4.1 Country Overview
          • 4.3.4.3.4.2 Market Sizing and Forecast
          • 4.3.4.3.4.2.1 Australia Interventional Ultrasound Market, by End User
        • 4.3.4.3.5 South Korea
          • 4.3.4.3.5.1 Country Overview
          • 4.3.4.3.5.2 Market Sizing and Forecast
          • 4.3.4.3.5.2.1 South Korea Interventional Ultrasound Market, by End User
        • 4.3.4.3.6 Rest-of-Asia-Pacific
          • 4.3.4.3.6.1 Country Overview
          • 4.3.4.3.6.2 Market Sizing and Forecast
          • 4.3.4.3.6.2.1 Rest-of-Asia-Pacific Interventional Ultrasound Market, by End User
  • 4.4 Latin America
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
    • 4.4.4 Market Sizing and Forecast
      • 4.4.4.1 Latin America Interventional Ultrasound Market, by Application
      • 4.4.4.2 Latin America Interventional Ultrasound Market, by End User
      • 4.4.4.3 Latin America Interventional Ultrasound Market, by Country
        • 4.4.4.3.1 Brazil
          • 4.4.4.3.1.1 Country Overview
          • 4.4.4.3.1.2 Market Sizing and Forecast
          • 4.4.4.3.1.2.1 Brazil Interventional Ultrasound Market, by End User
        • 4.4.4.3.2 Mexico
          • 4.4.4.3.2.1 Country Overview
          • 4.4.4.3.2.2 Market Sizing and Forecast
          • 4.4.4.3.2.3 Mexico Interventional Ultrasound Market, by End User
        • 4.4.4.3.3 Rest-of-Latin America
          • 4.4.4.3.3.1 Country Overview
          • 4.4.4.3.3.2 Market Sizing and Forecast
          • 4.4.4.3.3.2.1 Rest-of-Latin America Interventional Ultrasound Market, by End User
  • 4.5 Middle East and Africa
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
    • 4.5.4 Market Sizing and Forecast
      • 4.5.4.1 Middle East and Africa Interventional Ultrasound Market, by Application
      • 4.5.4.2 Middle East and Africa Interventional Ultrasound Market, by End User

5 Competitive Landscape and Company Profiles

  • 5.1 Competitive Landscape
  • 5.2 Company Profiles
    • 5.2.1 Canon Inc.
      • 5.2.1.1 Overview
      • 5.2.1.2 Top Products/Product Portfolio
      • 5.2.1.3 Top Competitors
      • 5.2.1.4 Target Customers
      • 5.2.1.5 Key Personal
      • 5.2.1.6 Analyst View
    • 5.2.2 DeepSight Technology, Inc.
      • 5.2.2.1 Overview
      • 5.2.2.2 Top Products/Product Portfolio
      • 5.2.2.3 Top Competitors
      • 5.2.2.4 Target Customers
      • 5.2.2.5 Key Personal
      • 5.2.2.6 Analyst View
    • 5.2.3 Edan Instruments
      • 5.2.3.1 Overview
      • 5.2.3.2 Top Products/Product Portfolio
      • 5.2.3.3 Top Competitors
      • 5.2.3.4 Target Customers
      • 5.2.3.5 Key Personal
      • 5.2.3.6 Analyst View
    • 5.2.4 Esaote SPA
      • 5.2.4.1 Overview
      • 5.2.4.2 Top Products/Product Portfolio
      • 5.2.4.3 Top Competitors
      • 5.2.4.4 Target Customers
      • 5.2.4.5 Key Personal
      • 5.2.4.6 Analyst View
    • 5.2.5 FUJIFILM Holdings Corporation
      • 5.2.5.1 Overview
      • 5.2.5.2 Top Products/Product Portfolio
      • 5.2.5.3 Top Competitors
      • 5.2.5.4 Target Customers
      • 5.2.5.5 Key Personal
      • 5.2.5.6 Analyst View
    • 5.2.6 GE HealthCare
      • 5.2.6.1 Overview
      • 5.2.6.2 Top Products/Product Portfolio
      • 5.2.6.3 Top Competitors
      • 5.2.6.4 Target Customers
      • 5.2.6.5 Key Personal
      • 5.2.6.6 Analyst View
    • 5.2.7 Konica Minolta, Inc.
      • 5.2.7.1 Overview
      • 5.2.7.2 Top Products/Product Portfolio
      • 5.2.7.3 Top Competitors
      • 5.2.7.4 Target Customers
      • 5.2.7.5 Key Personal
      • 5.2.7.6 Analyst View
    • 5.2.8 Koninklijke Philips N.V.
      • 5.2.8.1 Overview
      • 5.2.8.2 Top Products/Product Portfolio
      • 5.2.8.3 Top Competitors
      • 5.2.8.4 Target Customers
      • 5.2.8.5 Key Personal
      • 5.2.8.6 Analyst View
    • 5.2.9 Samsung Healthcare
      • 5.2.9.1 Overview
      • 5.2.9.2 Top Products/Product Portfolio
      • 5.2.9.3 Top Competitors
      • 5.2.9.4 Target Customers
      • 5.2.9.5 Key Personal
      • 5.2.9.6 Analyst View
    • 5.2.10 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
      • 5.2.10.1 Overview
      • 5.2.10.2 Top Products/Product Portfolio
      • 5.2.10.3 Top Competitors
      • 5.2.10.4 Target Customers
      • 5.2.10.5 Key Personal
      • 5.2.10.6 Analyst View
    • 5.2.11 Siemens Healthineers AG
      • 5.2.11.1 Overview
      • 5.2.11.2 Top Products/Product Portfolio
      • 5.2.11.3 Top Competitors
      • 5.2.11.4 Target Customers
      • 5.2.11.5 Key Personal
      • 5.2.11.6 Analyst View
    • 5.2.12 SonoScape Medical Corp.
      • 5.2.12.1 Overview
      • 5.2.12.2 Top Products/Product Portfolio
      • 5.2.12.3 Top Competitors
      • 5.2.12.4 Target Customers
      • 5.2.12.5 Key Personal
      • 5.2.12.6 Analyst View

6 Research Methodology

  • 6.1 Data Sources
    • 6.1.1 Primary Data Sources
    • 6.1.2 Secondary Data Sources
    • 6.1.3 Data Triangulation
  • 6.2 Market Estimation and Forecast
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦